Evidence map›Paper›PMID 32732767›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2020

Costs and Cost-Effectiveness of the Patient-Centered HIV Care Model: A Collaboration Between Community-Based Pharmacists and Primary Medical Providers.

Ram K Shrestha, Jon C Schommer, Michael S Taitel, Oscar W Garza, Nasima M Camp, Osayi E Akinbosoye, Patrick G Clay, Kathy K Byrd, Patient-centered HIV Care Model Team

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Ram K ShresthaDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
Jon C SchommerDepartment of Pharmaceutical Care & Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, MN.
Michael S TaitelHealth Analytics, Research, and Reporting, Walgreen Co., Deerfield, IL.
Oscar W GarzaDepartment of Pharmaceutical Care & Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, MN.
Nasima M CampDepartment of Health, Research, Informatics, and Technology, ICF, Atlanta, GA.
Osayi E AkinbosoyePharmacy Analytics and Global Insights, Walgreen Co., Deerfield, IL.
Patrick G ClayDepartment of Pharmacotherapy, University of North Texas Health Science Center System College of Pharmacy, Fort Worth, TX.
Kathy K ByrdDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
Patient-centered HIV Care Model Team
Centers for Disease Control and Prevention · USAstellas Pharma (Japan) · JPDeerfield (United States) · USICF International (United States) · USUniversity of Louisiana at Monroe · USUniversity of Minnesota · USUniversity of North Texas System · US

Funding

Intramural CDC HHS CC999999NCHHSTP CDC HHS U65 PS004275
6 · The paper itself

Abstract

backgroundThe patient-centered HIV care model (PCHCM) is an evidence-informed structural intervention that integrates community-based pharmacists with primary medical providers to improve rates of HIV viral suppression. This report assesses the costs and cost-effectiveness of the PCHCM.

settingPatient-centered HIV care model.

methodsThree project sites, each composed of a medical clinic and 1 or 2 community-based HIV-specialized pharmacies, were included in the analyses. PCHCM required patient data sharing between medical providers and pharmacists and collaborative therapy-related decision making. Intervention effectiveness was measured as the incremental number of patients virally suppressed (HIV RNA <200 copies/mL at the last test in a 12-month measurement period). Microcosting direct measurement methods were used to estimate intervention costs. The cost per patient, cost per patient visit, and incremental cost per patient virally suppressed were calculated from the health care providers' perspective. Additionally, the number of HIV transmissions averted, lifetime HIV treatment cost saved, quality-adjusted life years (QALYs) saved, and cost per QALY saved were calculated from the societal perspective, using standard methods and reported values from the published literature.

resultsOverall, the PCHCM annual intervention cost for the 3 project sites was $226,741. The average cost per patient, cost per patient visit, and incremental cost per patient virally suppressed were $813, $48, and $5,039, respectively. The intervention averted 2.75 HIV transmissions and saved 12.22 QALYs and nearly $1.28 million in lifetime HIV treatment costs. The intervention was cost saving overall and at each project site.

conclusionsThe PCHCM can be delivered at a relatively low cost and is a cost-saving intervention to assist patients in achieving viral suppression and preventing HIV transmission.

Indexed as

Health Care CostsPharmacistsPhysicians, Primary CareAnti-HIV AgentsCost-Benefit AnalysisHIV-1HIV InfectionsHumansPatient-Centered CareAnti-HIV Agents

Identifiers

PMID32732767
PMCPMC8549679
OpenAlexW3046717420

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.